6月1日，荣昌生物盘中下跌5.08%，报78.45港元/股，成交额3.05亿港元。
消息面上，美国议员近期提议将生物技术纳入COINS法案管制范畴，限制美国资本流入中国创新药企，叠加市场传闻国内拟对创新药海外BD交易增设前置审批，双向监管壁垒抬升令板块估值逻辑承压。此外，东方证券近期减持荣昌生物16万股，ETF资金连续多日净流出，行业整体面临资金转向AI等赛道的风格切换阵痛，创新药出海预期受挫成为压制估值的核心因素。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.